This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, M.-H. Articles by Wu, K.-J. Search for Related Content PubMed PubMed Citation Articles by Yang, M.-H. Articles by Wu, K.-J.

Increased NBS1 Expression Is a Marker of Aggressive Head and Neck Cancer and Overexpression of NBS1 Contributes to Transformation

Authors' Affiliations: Institutes of ¹ Clinical Medicine and ² Biochemistry and Molecular Biology, National Yang-Ming University; ³ Department of Pathology, ⁴ Division of Medical Oncology, Department of Medicine, and ⁵ Department of Otolaryngology, Taipei Veterans General Hospital; ⁶ Graduate Institute of Microbiology, College of Medicine, National Taiwan University, Taipei, Taiwan

Requests for reprints: Kou-Juey Wu, Institute of Biochemistry and Molecular Biology, National Yang-Ming University, No. 155, Li-Nong Street, Sec. 2, Peitou, Taipei 112, Taiwan. Phone: 886-228267328; Fax: 886-228202449; E-mail: kjwu2{at}ym.edu.tw.

Purpose: Head and neck squamous cell carcinoma (HNSCC) represents the sixth most frequent type of cancer worldwide. However, the molecular genetic alterations underlying its malignant behavior and progression are little known. We showed previously that c-MYC directly activates the expression of the DNA double-strand break repair gene NBS1, and NBS1 overexpression contributes to transformation. Here, we investigate the role of NBS1 overexpression in HNSCC.

Experimental Design: Immunohistochemistry analysis of NBS1 expression was done in 81 locally advanced HNSCC patients. Real-time PCR and Western blot analysis were used to confirm immunohistochemistry results. Human hypopharyngeal cancer cell lines (FADU) with overexpressing NBS1 (FADUNBS) or inducible short interference RNA to repress endogenous NBS1 (FADUNBSi) were generated by stable transfection. Soft agar clonogenicity assay was used to determine the transformation activity. Western blot analysis and phosphatidylinositol 3-kinase (PI3K) assay were done to evaluate the signaling pathways that were involved.

Results: NBS1 overexpression was identified in 45% of advanced HNSCC patients. It was an independent marker of poor prognosis. NBS1 expression levels correlated with the transformation activity of FADU clones and also correlated with the phosphorylation levels of Akt and its downstream target mammalian target of rapamycin (mTOR). PI3K activity was increased in NBS1-overexpressing FADU clones. NBS1 overexpression also correlated with increased Akt phosphorylation levels in tumor samples.

Conclusions: Increased NBS1 expression is a significant prognostic marker of advanced HNSCC, and the underlying mechanism may involve the activation of the PI3K/Akt pathway.

This article has been cited by other articles:

				B. Culjkovic, K. Tan, S. Orolicki, A. Amri, S. Meloche, and K. L.B. Borden The eIF4E RNA regulon promotes the Akt signaling pathway J. Cell Biol., April 3, 2008; 181(1): 51 - 63. [Abstract] [Full Text] [PDF]

				T. Kato, N. Sato, S. Hayama, T. Yamabuki, T. Ito, M. Miyamoto, S. Kondo, Y. Nakamura, and Y. Daigo Activation of Holliday Junction Recognizing Protein Involved in the Chromosomal Stability and Immortality of Cancer Cells Cancer Res., September 15, 2007; 67(18): 8544 - 8553. [Abstract] [Full Text] [PDF]

				L. Rink, A. Slupianek, T. Stoklosa, M. Nieborowska-Skorska, K. Urbanska, I. Seferynska, K. Reiss, and T. Skorski Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells Blood, July 15, 2007; 110(2): 651 - 660. [Abstract] [Full Text] [PDF]

				K. L. Bennett, B. Hackanson, L. T. Smith, C. D. Morrison, J. C. Lang, D. E. Schuller, F. Weber, C. Eng, and C. Plass Tumor Suppressor Activity of CCAAT/Enhancer Binding Protein {alpha} Is Epigenetically Down-regulated in Head and Neck Squamous Cell Carcinoma Cancer Res., May 15, 2007; 67(10): 4657 - 4664. [Abstract] [Full Text] [PDF]